Loading organizations...
§ Private Profile · 900 N Point Pkwy Ste 200, Alpharetta, Georgia, 30005, United States
Biopharmaceutical company developing treatments for serious eye diseases via its suprachoroidal microinjection platform.
Clearside Biomedical is an Alpharetta, Georgia-based biopharmaceutical company that develops treatments for serious eye diseases using a proprietary suprachoroidal microinjection platform. The publicly traded firm focuses on delivering targeted therapeutics to the back of the eye for conditions such as diabetic macular edema, retinal vein occlusion, uveitis, and wet age-related macular degeneration. Operating with a team of 21 to 50 employees, the NASDAQ-listed enterprise has raised $80 million across two venture funding rounds and maintains an estimated enterprise value of $102 million. The company's core delivery technology was initially discovered through a research collaboration with Mark Prausnitz, while its corporate development has been backed by early investors like Hatteras Venture Partners and led by current chief executive George Lasezkay. Clearside Biomedical was founded in 2012 by Daniel White and Ben Yerxa.
Clearside Biomedical has raised $48.0M across 4 funding rounds.
Clearside Biomedical has raised $48.0M in total across 4 funding rounds.
Clearside Biomedical is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapies delivered to the back of the eye using its proprietary suprachoroidal space (SCS) injection platform. The company’s flagship technology, the SCS Microinjector®, enables precise delivery of drugs directly to the suprachoroidal space, a novel route that targets sight-threatening ocular diseases more effectively. Clearside serves patients with serious retinal conditions such as macular edema associated with uveitis and wet age-related macular degeneration (AMD), aiming to improve vision outcomes where traditional treatments have limitations. Their FDA-approved product, XIPERE® (triamcinolone acetonide injectable suspension), exemplifies their innovative approach, with ongoing clinical development programs expanding into multiple retinal diseases[1][3][5].
Founded in 2011, Clearside Biomedical emerged from the vision of leveraging the suprachoroidal space as a new drug delivery route to the back of the eye, an area notoriously difficult to treat. The company was established by experts in ophthalmology and drug delivery technologies who recognized the potential to improve treatment precision and patient outcomes. Early validation came through the development and FDA approval of XIPERE®, marking the first suprachoroidal-administered product on the market. This milestone set the stage for Clearside’s evolution into a leader in suprachoroidal delivery, with strategic partnerships enhancing its clinical pipeline and commercial capabilities[2][3].
Clearside Biomedical rides the growing trend of precision drug delivery in ophthalmology, addressing the significant unmet need for effective treatments of retinal diseases that cause irreversible vision loss. The timing is favorable due to an aging global population and increasing prevalence of conditions like AMD and diabetic macular edema. Market forces such as rising healthcare focus on minimally invasive therapies and improved patient compliance further support Clearside’s approach. By pioneering suprachoroidal delivery, Clearside influences the broader ecosystem by setting new standards for ocular drug administration and fostering innovation partnerships that could reshape retinal disease management[1][3][4].
Looking ahead, Clearside Biomedical is positioned to advance its clinical pipeline, particularly the CLS-AX program targeting wet AMD, which is in Phase 3 trials. Continued regulatory approvals and commercialization of suprachoroidal therapies could significantly expand their market footprint. Trends such as personalized medicine and combination therapies may further enhance the value of their delivery platform. As Clearside matures, its influence may grow beyond ophthalmology, potentially inspiring new drug delivery innovations in other medical fields. The company’s pioneering role in suprachoroidal delivery remains a compelling foundation for future growth and impact on vision care[1][2][3].
Clearside Biomedical has raised $48.0M across 4 funding rounds. Most recently, it raised $20.0M Series C in December 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 3, 2015 | $20M Series C | — | AJU IB Investment, Cormorant Asset Management, Perceptive Advisors, Rock Springs Capital | Announced |
| Sep 1, 2014 | $16M Series B | — | Hatteras Venture Partners, Georgia Research Alliance, Mountain Group Partners, Rusnanomedinvest, Santen Pharmaceutical | Announced |
| Feb 1, 2013 | $8M Series A | — | Hatteras Venture Partners, Georgia Research Alliance, Kenan Flagler Business School, Mountain Group Partners, Schalon Newton | Announced |
| Jan 1, 2012 | $4M Series A | Hatteras Venture Partners | Henry Edelhauser, Mark Prausnitz | Announced |
Clearside Biomedical has raised $48.0M in total across 4 funding rounds.
Clearside Biomedical's investors include AJU IB Investment, Cormorant Asset Management, Perceptive Advisors, Rock Springs Capital, Hatteras Venture Partners, Georgia Research Alliance, Mountain Group Partners, RusnanoMedInvest, Santen Pharmaceutical, Kenan Flagler Business School, Schalon Newton, Henry Edelhauser.